Bellerophon rises on nod to start trial in China

Bellerophon Therapeutics

09/02/2023 14:48

** Shares of drug developer Bellerophon Therapeutics Inc
 BLPH.O  rise 6% to $1.76
    ** Says Center for Drug Evaluation of China's National
Medical Products Administration has cleared its application to
start a late stage trial of INOpulse
    ** The application is to support the registration of
INOpulse for the treatment of a type of lung disease in China
    ** The main goal of the study is moderate to vigorous
physical activity and will be conducted in collaboration with
Bellerophon's regional partner, Baylor BioSciences
    ** INOpulse delivery system is being developed for treatment
of patients with pulmonary hypertension associated with
interstitial lung disease
    ** Stock fell ~71% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))